The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers
Open accessAbstract
Background— The novel anticoagulant fondaparinux proved to be effective and safe in the postoperative prevention of venous thrombosis. Current phase III trials with this synthetic selective factor Xa inhibitor focus on its use in the treatment of patients with venous and arterial thrombosis. As with any anticoagulant therapy, there is a risk of bleeding complications; hence, a strategy to reverse the effects of fondaparinux is desirable. The aim of this study was to investigate whether recombinant factor VIIa (rFVIIa) could neutralize the anticoagulant effects of subcutaneously administered fondaparinux. Methods and Results— In a randomized, placebo-controlled design, 16 healthy male subjects received either a single subcutaneous dose of fondaparinux (10 mg) and a single intravenous bolus of rFVIIa (90 μg/kg; n=8), fondaparinux and placebo (n=4), or placebo and rFVIIa (n=4). Fondaparinux (or placebo) was administered 2 hours before rFVIIa (or placebo). Injection of rFVIIa after fondaparinux normalized the prolonged activated partial thromboplastin and prothrombin times and reversed the decrease in prothrombin activation fragments 1+2 (F 1+2 ), as observed with fondaparinux alone. Thrombin-generation time and endogenous thrombin potential, which were inhibited by fondaparinux, normalized up to 6 hours after rFVIIa injection. Conclusions— rFVIIa is capable of normalizing coagulation times and thrombin generation during fondaparinux treatment. The duration of this effect ranged from 2 to 6 hours after rFVIIa injection. These results suggest that rFVIIa may be useful to reverse the anticoagulant effect of fondaparinux in case of serious bleeding complications or need for acute surgery during treatment with fondaparinux.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bauer, K. A., Eriksson, B. I., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011099 · Cited by 666
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Olson, S. T., Björk, I., Sheffer, R., Craig, P. A., Shore, J. D., & Choay, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42309-5 · Cited by 470
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement
Turpie, A. G. G., Gallus, A. S., & Hoek, J. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440901 · Cited by 380
The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study
Hay, C. R. M., Negrier, C., & Ludlam, C. A. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1665434 · Cited by 344
Rosing, J., Tans, G., Nicolaes, G. A. F., Thomassen, M. C. L. G. D., Van Oerle, R., Van DerPloeg, P. M. E. N., Heijnen, P., Hamulyak, K., & Hemker, H. C. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.192707.x · Cited by 325
de Jonge, E., Dekkers, P. E. P., Creasey, A. A., Hack, C. E., Paulson, S. K., Karim, A., Kesecioglu, J., Levi, M., van Deventer, S. J. H., & van der Poll, T. (2000) · Blood · doi:10.1182/blood.v95.4.1124.002k20_1124_1129 · Cited by 259
Self-citationAbraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff, D., Dal Nogare, A., Postier, R., Hempelmann, G., Butler, T., Martin, E., et al. (2001) · Critical Care Medicine · doi:10.1097/00003246-200111000-00007 · Cited by 253
Erhardtsen, E., Nony, P., Dechavanne, M., Ffrench, P., Boissel, J. P., & Hedner, U. (1998) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199811000-00003 · Cited by 171
Coussement, P. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2777 · Cited by 169
Cited by
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Self-citationHirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Frontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006221 · Cited by 677
Self-citationMarlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J., & Pernod, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0179 · Cited by 501
Metadata
- Authors
- Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M.
- Venue
- Circulation
- Published
- 2002-11-12
- Volume
- 106
- Issue
- 20
- Pages
- 2550-2554
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2170550513
- Cited by
- 316
- References
- 13
- FWCI
- 9.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers. https://app.cochat.ai/papers/10.1161/01.cir.0000038501.87442.02
- The paper
- Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M. (2002). Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers. Circulation. https://doi.org/10.1161/01.cir.0000038501.87442.02
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.